8-K: Intelligent Bio Solutions Enacts 1-for-12 Reverse Stock Split to Meet Nasdaq Listing Requirements

Intelligent Bio Solutions implemented a 1-for-12 reverse stock split to increase its share price and comply with Nasdaq's minimum listing requirements.

Summary

• Intelligent Bio Solutions Inc. has completed a 1-for-12 reverse stock split of its common stock.
• The reverse stock split became effective on January 26, 2024, at 5:00 PM Eastern Time.
• The primary goal of the reverse stock split is to increase the company's per share trading price and meet Nasdaq's minimum share price listing requirement.
• As a result of the split, every 12 shares of common stock were combined into one share.
• The number of outstanding shares decreased from approximately 17,930,673 to approximately 1,494,223.
• The number of authorized shares remains at 100 million.
• Proportionate adjustments were made to stock options, restricted stock units, and warrants.
• The company's common stock began trading on a split-adjusted basis on January 29, 2024, under the same ticker symbol INBS.
• The par value of the common stock remains at $0.01 per share.
• A new CUSIP number (36151G600) was assigned to the post-split common stock.

Sentiment

Score: 4

Explanation: The document primarily discusses a reverse stock split, which is generally a negative sign, indicating the company is struggling to maintain its share price. While the company is taking steps to remain listed on the Nasdaq, the underlying reason for the split is concerning.

Positives

• The reverse stock split is expected to bring the company into compliance with Nasdaq's minimum share price listing requirement.
• The reverse stock split will not alter any stockholders percentage interest in the Companys equity, except to the extent that the reverse split results in some stockholders owning a fractional share.

Negatives

• The reverse stock split reduces the number of outstanding shares, which could potentially impact trading volume.
• The reverse stock split was necessary to avoid delisting from the Nasdaq.

Risks

• The company's ability to maintain compliance with Nasdaq listing requirements remains a risk.
• The reverse stock split may not be sufficient to maintain the share price above the minimum threshold.
• The company's future success depends on its ability to develop and commercialize its drug and diagnostic tests.

Future Outlook

The company's future success depends on its ability to develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals.

Management Comments

• The reverse stock split is primarily intended to increase the Companys per share trading price and bring the Company into compliance with Nasdaqs listing requirement regarding minimum share price.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low share prices. This action is often a sign of financial distress or a need to regain compliance with listing requirements.

Comparison to Industry Standards

• Reverse stock splits are a common practice for companies facing delisting from exchanges like Nasdaq, similar to actions taken by other biotech and medical technology companies in similar situations.
• The 1-for-12 ratio is within the typical range for reverse stock splits, which can vary widely depending on the company's specific circumstances and the desired post-split share price.
• Companies like Cassava Sciences and Ocugen have also undertaken reverse stock splits to maintain their Nasdaq listings, demonstrating that this is a common strategy in the biotech sector.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but their percentage ownership will remain the same, except for fractional shares.
• The reverse stock split is intended to benefit shareholders by maintaining the company's listing on the Nasdaq.

Next Steps

• The company will continue to trade on the Nasdaq under the symbol INBS.
• The company will focus on developing and commercializing its drug and diagnostic tests.

Key Dates

Keywords

reverse stock split, Nasdaq, share price, listing requirements, common stock, INBS, stock options, warrants, equity awards